Three drugs vs. one: major trial aims to keep blood cancer at bay after transplant
NCT ID NCT02659293
Summary
This large, Phase 3 trial is testing whether adding two extra drugs to a standard maintenance therapy is better at preventing multiple myeloma from coming back after a stem cell transplant. It will enroll about 180 adults whose cancer is stable after their transplant. The main goal is to see which approach keeps patients in remission longer and with fewer side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Polish Myeloma Consortium
Poznan, Poland
-
University of Chicago
Chicago, Illinois, 60637, United States
-
Wayne State University - Karmanos Cacner Institute
Detroit, Michigan, 48201, United States
Conditions
Explore the condition pages connected to this study.